AgomAb Therapeutics (AGMB) Stock Price, Quote, News & History | Benzinga

AgomAb Therapeutics NV (AGMB) Stock Price, Quote, News & History

AGMBNASDAQ

Trade with Public

Trade with Public

$15.00

0.503.45%

At close: Aug 10, 5:00 PM EST

$15.26

0.261.73%

After Hours: Aug 5, 9:03 AM EST

Earnings: H1 2026 Earnings were released on Thu Aug 6th, after the market close

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Stock Report

Key Statistics

Open

$14.53

Close

$15.00

Volume / Avg.

87.44K / 94.45K

Day Range

$13.64 - $15.44

52 Wk Range

8.75 - 17.82

Market Cap

$751.52M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

63

Short Interest

3.05%

Days to Cover

14.55

Recent Agomab Therapeutics NV News

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability ---- Study initiation on track, with

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI

Avi Kapoor

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what analysts say about buying CRDO stock.

Avi Kapoor

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.

Avi Kapoor

Mattel Posts Downbeat Earnings, Joins Lyft, Robinhood And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-51.74M

Investing Cash Flow (TTM)

-33.00M

Financing Cash Flow (TTM)

-338.00K

Free Cash Flow (TTM)

-51.75M

Capital Expenditure (TTM)

-4.00K

Net Change in Cash (TTM)

-85.09M

Analyst Trends and Forecast

3

Mar

1

Jun

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$425.04M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.33

Earnings Yield % (TTM)

-10.79%

Earnings Yield % (FWD)

-12.23%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$6.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$338.00K

Total Cash

$86.42M

Debt to Equity

0.01

Issuance of Debt (TTM)

-$338.00K

Repayment of Debt (TTM)

-$338.00K

Key Statistics

Open

$14.53

Close

$15.00

Volume / Avg.

87.44K / 94.45K

Day Range

$13.64 - $15.44

52 Wk Range

8.75 - 17.82

Market Cap

$751.52M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

63

Short Interest

3.05%

Days to Cover

14.55

About

Sector

Health Care

Industry

Pharmaceuticals

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need....

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy AgomAb Therapeutics (AGMB) stock?

A

You can purchase shares of AgomAb Therapeutics (NASDAQ:AGMB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are AgomAb Therapeutics (AGMB) competitors?

A

Other companies in AgomAb Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for AgomAb Therapeutics (AGMB) stock?

A

AgomAb Therapeutics has a consensus price target of $33.00.

Q

What is the current price for AgomAb Therapeutics (AGMB)?

A

The stock price for AgomAb Therapeutics (NASDAQ: AGMB) is $15.26 last updated August 5, 2026 at 9:03 AM EDT.

Q

Does AgomAb Therapeutics (AGMB) pay a dividend?

A

There are no upcoming dividends for AgomAb Therapeutics.

Q

When is AgomAb Therapeutics (NASDAQ:AGMB) reporting earnings?

A

AgomAb Therapeutics does not have any upcoming earnings scheduled.

Q

Is AgomAb Therapeutics (AGMB) going to split?

A

There is no upcoming split for AgomAb Therapeutics.

Q

What sector and industry does AgomAb Therapeutics (AGMB) operate in?

A

AgomAb Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.